Eldelumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameEldelumab
Drug Alias Name艾地芦人单抗eldelumab埃迪鲁单抗eldelumabumAnti-IP10 antibody +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionC-X-C motif chemokine ligand 10 antagonists
TargetsC-X-C motif chemokine ligand 10
Therapy Area/IndicationsCrohn DiseaseColitis, UlcerativeArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[14] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedarex IncBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb Srlcompany
Active IndicationsN/A
Inactive IndicationsCrohn DiseaseColitis, UlcerativeArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG